How do changes in pain severity levels correspond to changes in health status and function in patients with painful diabetic peripheral neuropathy?
Hoffman
Deborah L
DL
Pfizer, Inc., New London, CT, USA Pfizer, Inc., New York, NY, USA.
Sadosky
Alesia
A
Dukes
Ellen M
EM
Alvir
Jose
J
D000203:Activities of Daily Living / Q000523:psychology*; D000328:Adult; D000368:Aged; D000700:Analgesics / Q000008:administration & dosage; D001007:Anxiety / Q000188:drug therapy / Q000209:etiology / Q000523:psychology; D003929:Diabetic Neuropathies / Q000145:classification* / Q000175:diagnosis* / Q000188:drug therapy; D005260:Female; D006304:Health Status; D006801:Humans; D008297:Male; D008875:Middle Aged; D017063:Outcome Assessment, Health Care; D010147:Pain Measurement / Q000379:methods* / Q000592:standards; D017060:Patient Satisfaction; D010919:Placebos; D000069583:Pregabalin; D011788:Quality of Life / Q000523:psychology*; D012647:Self-Assessment; D012720:Severity of Illness Index; D013315:Stress, Psychological / Q000188:drug therapy / Q000209:etiology / Q000523:psychology; D011795:Surveys and Questionnaires; D005680:gamma-Aminobutyric Acid / Q000008:administration & dosage / Q000031:analogs & derivatives
D000700:Analgesics; D010919:Placebos; D000069583:Pregabalin; D005680:gamma-Aminobutyric Acid